Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis.

about

Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis.

Item

http://www.wikidata.org/entity/Q38648469

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Drug survival of second biolog ...... nterventional cohort analysis.

@en

type

Item

label

Drug survival of second biolog ...... nterventional cohort analysis.

@en

prefLabel

Drug survival of second biolog ...... nterventional cohort analysis.

@en

P1476

Drug survival of second biolog ...... interventional cohort analysis

@en

P2093

Istvan Majer

http://www.w3.org/2001/XMLSchema#string

Marieke Heisen

http://www.w3.org/2001/XMLSchema#string

Sabrina Mueller

http://www.w3.org/2001/XMLSchema#string

Thomas Wilke

http://www.w3.org/2001/XMLSchema#string

P2860

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

[Good Practice of Secondary Data Analysis (GPS): guidelines and recommendations].

Assessing the validity of diagnostic information in administrative health care utilization data: experience in Saskatchewan.

Studying prescription drug use and outcomes with medicaid claims data: strengths, limitations, and strategies

Review on use of German health insurance medication claims data for epidemiological research.

DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort.

Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register.

P2888

s12891-017-1684-0

P304

332

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12891-017-1684-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sze Chim Lee

P577

2017-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1090944276

http://www.w3.org/2001/XMLSchema#string

P698

28764705

http://www.w3.org/2001/XMLSchema#string

P932

5540414

http://www.w3.org/2001/XMLSchema#string